CDK4 and neoplasm: While these mechanisms of resistance and their relevance in the clinic are currently being examined, a few key questions arise—Do these resistance mechanisms alter ER-driven tumor growth, and does an ER-targeted agent continue to be effective in patients with prior CDK4/6i therapy?